Literature DB >> 26676777

Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques.

S Abigail Smith1, Katie M Kilgore1, Sudhir Pai Kasturi1, Bali Pulendran2, Eric Hunter2, Rama R Amara3, Cynthia A Derdeyn4.   

Abstract

UNLABELLED: Mucosal surfaces are vulnerable to human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection and thus are key sites for eliciting vaccine-mediated protection. Vaccine protocols carried out at the Yerkes Primate Research Center utilized SIVmac239-based immunization strategies with intrarectal and intravaginal SIVsmE660 challenge of rhesus macaques. We investigated whether there were genetic signatures associated with SIVsmE660 intrarectal and intravaginal transmissions in vaccinated and unvaccinated monkeys. When transmitted/founder (T/F) envelope (Env) sequences from 49 vaccinated and 15 unvaccinated macaques were compared to each other, we were unable to identify any vaccine breakthrough signatures. In contrast, when the vaccinated and control T/F Envs were combined and compared to the challenge stock, residues at gp120 positions 23, 45, 47, and 70 (Ile-Ala-Lys-Asn [I-A-K-N]) emerged as signatures of mucosal transmission. However, T/F Envs derived from intrarectal and intravaginal infections were not different. Our data suggest that the vaginal and rectal mucosal environments both imposed a strong selection bias for SIVsmE660 variants carrying I-A-K-N that was not further enhanced by immunization. These findings, combined with the strong conservation of A-K-N in most HIV-2/SIVsmm isolates and the analogous residues in HIV-1/SIVcpz isolates, suggest that these residues confer increased transmission fitness to SIVsmE660. IMPORTANCE: Most HIV-1 infections occur across a mucosal barrier, and it is therefore important to understand why these sites are vulnerable and how to protect them with a vaccine. To gain insight into these questions, we studied rhesus macaques that were vaccinated with SIVmac239 and unvaccinated controls to determine whether the SIVsmE660 viral variants that infected these two groups were different. We did not find differences between viral variants in the absence versus presence of vaccination-induced immunity, but we did find that the SIVsmE660 viral variants that infected the monkeys, regardless of vaccination, were different from the dominant population found in the viral challenge inoculum. Our data suggest that the mucosal environments of the vagina and rectum both impose a strong selection for the SIVsmE660 variants in the challenge inoculum that are most like SIV and HIVs that circulate in nature.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26676777      PMCID: PMC4734005          DOI: 10.1128/JVI.02711-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

Authors:  Zahra F Parker; Shilpa S Iyer; Craig B Wilen; Nicholas F Parrish; Kelechi C Chikere; Fang-Hua Lee; Chuka A Didigu; Reem Berro; Per Johan Klasse; Benhur Lee; John P Moore; George M Shaw; Beatrice H Hahn; Robert W Doms
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

2.  Risk of immunodeficiency virus infection may increase with vaccine-induced immune response.

Authors:  Matthias Tenbusch; Ralf Ignatius; Vladimir Temchura; Ghulam Nabi; Bettina Tippler; Guillaume Stewart-Jones; Andres M Salazar; Ülrike Sauermann; Christiane Stahl-Hennig; Klaus Uberla
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

3.  Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.

Authors:  Peng Xiao; L Jean Patterson; Seraphin Kuate; Egidio Brocca-Cofano; Michael A Thomas; David Venzon; Jun Zhao; Janet DiPasquale; Claudio Fenizia; Eun Mi Lee; Irene Kalisz; Vaniambadi S Kalyanaraman; Ranajit Pal; David Montefiori; Brandon F Keele; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Correlates of relative resistance against low-dose rectal simian immunodeficiency virus challenges in peripheral blood mononuclear cells of vaccinated rhesus macaques.

Authors:  Raj Kurupati; Steve Tuyishime; Andrew V Kossenkov; Marina Sazanovich; Larissa H Haut; Marcio O Lasaro; Sarah J Ratcliffe; Steven E Bosinger; Diane G Carnathan; Mark Lewis; Louise C Showe; Guido Silvestri; Hildegund C J Ertl
Journal:  J Leukoc Biol       Date:  2012-12-27       Impact factor: 4.962

5.  Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.

Authors:  Fang-Hua Lee; Rosemarie Mason; Hugh Welles; Gerald H Learn; Brandon F Keele; Mario Roederer; Katharine J Bar
Journal:  J Virol       Date:  2015-09-30       Impact factor: 5.103

6.  Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.

Authors:  Bhavna Chohan; Dorothy Lang; Manish Sagar; Bette Korber; Ludo Lavreys; Barbra Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Selection of HIV variants with signature genotypic characteristics during heterosexual transmission.

Authors:  Manish Sagar; Oliver Laeyendecker; Sandra Lee; Jordyn Gamiel; Maria J Wawer; Ronald H Gray; David Serwadda; Nelson K Sewankambo; James C Shepherd; Jonathan Toma; Wei Huang; Thomas C Quinn
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

8.  Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.

Authors:  Michael Lopker; Juliet Easlick; Sarah Sterrett; Julie M Decker; Hannah Barbian; Gerald Learn; Brandon F Keele; James E Robinson; Hui Li; Beatrice H Hahn; George M Shaw; Katharine J Bar
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

9.  Phenotypic properties of transmitted founder HIV-1.

Authors:  Nicholas F Parrish; Feng Gao; Hui Li; Elena E Giorgi; Hannah J Barbian; Erica H Parrish; Lara Zajic; Shilpa S Iyer; Julie M Decker; Amit Kumar; Bhavna Hora; Anna Berg; Fangping Cai; Jennifer Hopper; Thomas N Denny; Haitao Ding; Christina Ochsenbauer; John C Kappes; Rachel P Galimidi; Anthony P West; Pamela J Bjorkman; Craig B Wilen; Robert W Doms; Meagan O'Brien; Nina Bhardwaj; Persephone Borrow; Barton F Haynes; Mark Muldoon; James P Theiler; Bette Korber; George M Shaw; Beatrice H Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-29       Impact factor: 11.205

10.  Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.

Authors:  Brandon F Keele; Hui Li; Gerald H Learn; Peter Hraber; Elena E Giorgi; Truman Grayson; Chuanxi Sun; Yalu Chen; Wendy W Yeh; Norman L Letvin; John R Mascola; Gary J Nabel; Barton F Haynes; Tanmoy Bhattacharya; Alan S Perelson; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more
  10 in total

Review 1.  Survivors Remorse: antibody-mediated protection against HIV-1.

Authors:  George K Lewis; Marzena Pazgier; Anthony L DeVico
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

2.  Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.

Authors:  Samantha Burton; Lori M Spicer; Tysheena P Charles; Sailaja Gangadhara; Pradeep B J Reddy; Tiffany M Styles; Vijayakumar Velu; Sudhir Pai Kasturi; Traci Legere; Eric Hunter; Bali Pulendran; Rama Amara; Peter Hraber; Cynthia A Derdeyn
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

3.  CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy.

Authors:  Emily K Cartwright; Lori Spicer; S Abigail Smith; David Lee; Randy Fast; Sara Paganini; Benton O Lawson; Melon Nega; Kirk Easley; Joern E Schmitz; Steven E Bosinger; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Jacob D Estes; Jeffrey D Lifson; Cynthia A Derdeyn; Guido Silvestri
Journal:  Immunity       Date:  2016-09-20       Impact factor: 31.745

4.  A high throughput lentivirus sieving assay identifies neutralization resistant Envelope sequences and predicts in vivo sieving.

Authors:  Nami Iwamoto; Rosemarie Mason; Jianfei Hu; Amy Ransier; Hugh Welles; Kaimei Song; Daniel Douek; Mario Roederer
Journal:  J Immunol Methods       Date:  2018-10-31       Impact factor: 2.303

5.  Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.

Authors:  S Abigail Smith; Samantha L Burton; William Kilembe; Shabir Lakhi; Etienne Karita; Matt Price; Susan Allen; Eric Hunter; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2016-11-16       Impact factor: 6.823

6.  Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine.

Authors:  Chu Wang; Chunlai Jiang; Nan Gao; Kaikai Zhang; Donglai Liu; Wei Wang; Zhe Cong; Chuan Qin; Vitaly V Ganusov; Guido Ferrari; Celia LaBranche; David C Montefiori; Wei Kong; Xianghui Yu; Feng Gao
Journal:  Viruses       Date:  2017-06-02       Impact factor: 5.048

7.  Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys.

Authors:  Brandon F Keele; Wenjun Li; Erica N Borducchi; Joseph P Nkolola; Peter Abbink; Bing Chen; Michael S Seaman; Dan H Barouch
Journal:  Nat Commun       Date:  2017-06-05       Impact factor: 14.919

8.  Reply to correspondence 'Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process' by Gonzalez et al., Retrovirology 2017.

Authors:  Corinna S Oberle; Carsten Magnus; Beda Joos; Peter Rusert; David Beauparlant; Roger Kouyos; Alexandra Trkola; Karin J Metzner; Huldrych F Günthard
Journal:  Retrovirology       Date:  2017-02-24       Impact factor: 4.602

9.  Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process.

Authors:  Mileidy Gonzalez; Anthony L DeVico; John L Spouge
Journal:  Retrovirology       Date:  2017-02-24       Impact factor: 4.602

10.  Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques.

Authors:  Shakti Singh; Eric G Ramírez-Salazar; Rami Doueiri; Antonio Valentin; Margherita Rosati; Xintao Hu; Brandon F Keele; Xiaoying Shen; Georgia D Tomaras; Guido Ferrari; Celia LaBranche; David C Montefiori; Jishnu Das; Galit Alter; Hung V Trinh; Christopher Hamlin; Mangala Rao; Frances Dayton; Jenifer Bear; Bhabadeb Chowdhury; Candido Alicea; Jeffrey D Lifson; Kate E Broderick; Niranjan Y Sardesai; Sandra J Sivananthan; Christopher B Fox; Steven G Reed; David J Venzon; Vanessa M Hirsch; George N Pavlakis; Barbara K Felber
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.